Evidence mapPaperPMID 34196879Full record

ArticleCellular and molecular neurobiology2022

Modulation of α7nAchR by Melatonin Alleviates Ischemia and Reperfusion-Compromised Integrity of Blood-Brain Barrier Through Inhibiting HMGB1-Mediated Microglia Activation and CRTC1-Mediated Neuronal Loss.

Shuang Chen, Yanyun Sun, Fei Li, Xinyu Zhang, Xiaoyan Hu, Xiaoyun Zhao, Yixuan Li, Hui Li, Jianliang Zhang, Wenlan Liu and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Programmed cell death and melatonin: A comprehensive review.Functional & integrative genomics · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. N-acetylserotonin alleviates retinal ischemia-reperfusion injuryInternational journal of ophthalmology · 2024
    Article
  14. Review
  15. Microglia at the blood brain barrier in health and disease.Frontiers in cellular neuroscience · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. CRTC1 is a potential target to delay aging-induced cognitive deficit by protecting the integrity of the blood-brain barrier via inhibiting inflammation.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Shuang Chen *Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Yanyun Sun *Institute of Neuroscience, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Fei Li *Hubei Key Laboratory of Wudang Local Chinese Medicine Research, School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, 442000, China.
Xinyu ZhangInstitute of Neuroscience, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Xiaoyan HuDepartment of Anatomy, Histology and Embrology, School of Basic Medical Sciences, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100069, China.
Xiaoyun ZhaoDepartment of Anatomy, Histology and Embrology, School of Basic Medical Sciences, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100069, China.
Yixuan LiDepartment of Anatomy, Histology and Embrology, School of Basic Medical Sciences, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100069, China.
Hui LiDepartment of Anatomy, Histology and Embrology, School of Basic Medical Sciences, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, 100069, China.
Jianliang ZhangDepartment of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100054, China.
Wenlan LiuThe Central Laboratory, Shenzhen Second People's Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen University School of Medicine, Shenzhen, 518035, China.
Guo-Qing ZhengDepartment of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, China. gq_zheng@sohu.com.
Xinchun JinInstitute of Neuroscience, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China. xinchunjin@gmail.com.ORCID http://orcid.org/0000-0002-5351-7914
Capital Medical University · CNSoochow University · CNWenzhou Medical University · CNHubei University of Medicine · CNShenzhen Second People's Hospital · CN

Funding

National Natural Science Foundation of China 81671149
6 · The paper itself

Abstract

The only food and drug administration (FDA)-approved drug currently available for the treatment of acute ischemic stroke is tissue plasminogen activator (tPA), yet the therapeutic benefits of this drug are partially outweighed by the increased risk of hemorrhagic transformation (HT). Analysis of the NIH trial has shown that cigarette smoking protected tPA-treated patients from HT; however, the underlying mechanism is not clear. Nicotinic acetylcholine receptors (nAChR) has shown anti-inflammatory effect and modulation nAChR could be a strategy to reduce ischemia/reperfusion-induced blood-brain barrier (BBB) damage. Since melatonin could regulate the expression of α7nAchR and melatonin's neuroprotective effect against ischemic injury is mediated via α7nAChR modulation, here, we aim to test the hypothesis that melatonin reduces ischemia and reperfusion (I/R)-induced BBB damage through modulation of α7nACh receptor (α7nAChR). Mice were subjected to 1.5 h ischemia and 24 h reperfusion and at the onset of reperfusion, mice received intraperitoneal administration (i.p.) of either drug or saline. Mice were randomly assigned into five groups: Saline; α7nAChR agonist PNU282987; Melatonin; Melatonin+Methyllycaconitine (MLA, α7nAChR antagonist), and MLA group. BBB permeability was assessed by detecting the extravasation of Evan's blue and IgG. Our results showed that I/R significantly increased BBB permeability accompanied by occludin degradation, microglia activation, and high mobility group box 1 (HMGB1) release from the neuron. In addition, I/R significantly induced neuronal loss accompanied by the decrease of CREB-regulated transcriptional coactivator 1 (CRTC1) and p-CREB expression. Melatonin treatment significantly inhibited the above changes through modulating α7nAChR. Taken together, these results demonstrate that melatonin provides a protective effect on ischemia/reperfusion-induced BBB damage, at least in part, depending on the modulation of α7nAChR.

Indexed as

HMGB1 ProteinIschemic StrokeMelatoninReceptors, Nicotinicalpha7 Nicotinic Acetylcholine ReceptorAnimalsBlood-Brain BarrierIschemiaMiceMicrogliaReperfusionTissue Plasminogen ActivatorTranscription Factorsalpha7 Nicotinic Acetylcholine ReceptorCrtc1 protein, mouseHMGB1 ProteinMelatoninReceptors, NicotinicTissue Plasminogen ActivatorTranscription FactorsBlood–brain barrierHMGB1MelatoninStrokeα7nAChR

Identifiers

PMID34196879
PMCPMC11421614
OpenAlexW3171143133

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.